***Background.*** Currently the CDC recommends the use of Interferon-Gamma Release Assays (IGRAs) as an alternative to tuberculin skin tests (TSTs) in the diagnosis of *M. tuberculosis* infection. IGRAs are typically preferred in persons who have received BCG or with poor rates of follow up evaluation. Additional situations where IGRAs may be useful include those in which increased sensitivity is indicated (such as a negative TST in someone at high risk, healthcare workers (HCWs) who have been told they have a history of latent tuberculosis (LTBI)), or to increase acceptance and adherence to treatment guidelines (in cases of foreign-born HCWs who believe their positive test is a result of BCG).

***Methods.*** A retrospective review of IGRA results done at Detroit Medical Center (DMC) HCWs was conducted from March 2013 to March 2014. During the period, 6,138 T-Spot TB test results were obtained (4,631 employees, 343 staff and 1164 commercial clients, contractors, volunteers, students). Epidemiologic data on these HCWs was abstracted and their IGRA results compared with prior diagnosis of LTBI (defined as a prior TST result or on the basis of LTBI by history).

***Results.*** T-Spot testing revealed 5,815 negative (94.7%), 249 positive (4.1%), and 74 invalid or borderline (1.2%) values. Prior latent TB infection (LTBI) status was known for 3,478. Of these persons, 732 (21.0%) had previously been determined to have LTBI (110 positive TST and 622 by history of LTBI), whereas only 214 (6.2%) tested positive on the T-Spot. When prior TSTs were negative (n = 2746), the T-Spot was negative 98.9% of the time. However, when prior LTBI history was positive (n = 732), the T-Spot was positive only 25% of the time.

***Conclusion.*** T-Spot testing is very specific in identification of HCW with LTBI. Chemoprophylaxis, when based on TST results or a history of LTBI would be recommended three times more frequently than when based on T-Spot results. The use of IGRA testing may help identify HCW with a history of LTBI who are most likely to benefit from treatment for LTBI.
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